Processa (PCSA) Chief Business Officer Lin Patrick Receives RSUs

What Happened Lin Patrick, Processa Pharmaceuticals' Chief Business & Strategy Officer, was granted 8,450 restricted stock units (RSUs) on July 26, 2026. The filing reports the acquisition as a derivative award at $0.00 per share (no cash exchanged). The RSUs vested upon grant but will not be distributed immediately — distribution is deferred under the terms described in the filing.

Key Details

• Transaction date: 2026-07-26; Form 4 filed 2026-07-28 (timely filing).
• Transaction type: Award/Grant (code A) of 8,450 RSUs; reported price $0.00 (derivative instrument).
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Footnote F1: Each RSU is a contingent right to one common share; although these RSUs vested on grant, distribution is delayed until the earlier of termination, six months after grant, change of control, or death.
• Footnote F2: Separately notes typical option vesting schedule (one-third after 1 year, then ratably over two years) — not directly part of this RSU grant detail.
• Footnote F3: Counts reflect a 1-for-25 reverse stock split effected December 17, 2025.

Context This is a compensation award (RSUs), not an outright purchase or sale. Because distribution of the shares is delayed, the award does not immediately increase transferable shares held by the insider. Awards are routine for executive compensation and do not by themselves indicate a buy/sell signal.